People with behavioral and psychological symptoms of dementia who received an average of 622 mg of sodium benzoate daily had similar primary and secondary outcomes, as well as similar safety results, compared with those who were given placebo, Taiwanese researchers reported in the Journal of Psychopharmacology. The findings prompted researchers to conclude that longer and higher-dose clinical trials are needed to gauge sodium benzoate's efficacy and safety for behavioral and psychological symptoms of dementia.
Sodium benzoate may not benefit patients with dementia
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.